주식/증권 ➡️ 중립

Is IART Still Attractive as Its Low Valuation Meets Execution Risks?

Yahoo Finance 08/19/2026 03:35:00 PM 8회

요약

Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.

원문 기사 보기

관련 뉴스

Schwab's Dividend ETF Has Gained 25% This Year. Is It Still Worth Buying?

Here are the key things Fed Chairman Kevin Warsh said — and didn’t say — while Americans were sleeping Thursday night

Stock Market: Will S&P 500 Open Up or Down Today?

Taiwan plans $4B Texas hub for AI, Nvidia suppliers

뉴스 목록으로